ストックスクリーナーアプリを入手
2.03
1.50%
0.03
アフターアワーズ：
2.00
-0.03
-1.48%
前日終値:
$2.00
開ける：
$1.98
24時間の取引高:
4.27M
Relative Volume:
0.90
時価総額：
$302.88M
収益：
$250.00K
当期純損益:
$-11.23M
株価収益率:
-0.4811
EPS:
-4.2191
ネットキャッシュフロー:
$-10.08M
1週間 パフォーマンス:
+23.78%
1か月 パフォーマンス:
+16.67%
6か月 パフォーマンス:
+239.46%
1年 パフォーマンス:
+93.33%
1日の値動き範囲:
$1.88
$2.05
1週間の範囲:
$1.605
$2.05
52週間の値動き範囲:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
名前
Palisade Bio Inc
セクター
電話
(858) 704-4900
住所
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.03 | 298.41M | 250.00K | -11.23M | -10.08M | -4.2191 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.13 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.61 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.85 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.23 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
285.30 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | Stifel | Buy |
| 2026-01-09 | 開始されました | B. Riley Securities | Buy |
| 2025-12-29 | 開始されました | Piper Sandler | Overweight |
Palisade Bio Inc (PALI) 最新ニュース
RSI Check: Will Palisade Bio Inc outperform its industry peers2026 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Macro: Can Palisade Bio Inc maintain sales growth2025 Buyback Activity & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-03-07 13:46:23 - baoquankhu1.vn
US Market Recap: Will Palisade Bio Inc stock recover after earningsTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Treasury Yields: Will Palisade Bio Inc benefit from current market trends2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Bitget
Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference - MarketBeat
Palisade Bio (NASDAQ:PALI) Upgraded to "Hold" at Wall Street Zen - MarketBeat
PALI Should I Buy - Intellectia AI
PALI: Advancing a once-daily, gut-restricted PDE4 inhibitor with strong funding and pivotal trials ahead - TradingView
Palisade Bio (NASDAQ:PALI) Now Covered by Stifel Nicolaus - MarketBeat
Stifel Initiates Palisade Bio at Buy With $5 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Palisade Bio (PALI) Sees New 'Buy' Rating from Stifel | PALI Sto - GuruFocus
Stifel Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - Nasdaq
Stifel initiates Palisade Bio stock with buy rating on IBD drug - Investing.com Australia
PALI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stifel initiates Palisade Bio stock with buy rating on IBD drug By Investing.com - Investing.com Canada
Palisade Bio Strengthens Advisory Board, Fast-tracks Key Research Developments - timothysykes.com
Palisade Bio presents ulcerative colitis drug trial data at ECCO By Investing.com - Investing.com India
Palisade Bio presents ulcerative colitis drug trial data at ECCO - Investing.com
Palisade Bio, Inc. Presents Phase 1b Data Demonstrating Localized Target Engagement and Early Clinical Response of PALI-2108 in Ulcerative Colitis at ECCO 2026 - Quiver Quantitative
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 - Bitget
Palisade Bio Reports Rapid Clinical, Histologic and New - GlobeNewswire
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest - Defense World
Palisade Bio appoints IBD expert to clinical advisory board By Investing.com - Investing.com Canada
Perceptive fund discloses 9.99% Palisade Bio (PALI) ownership stake - Stock Titan
Palisade Bio appoints IBD expert to clinical advisory board - Investing.com
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board - Bitget
Palisade Bio Strengthens Clinical Advisory Board with Appointment of Dr. Bram Verstockt to Advance PALI-2108 Development in Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Ulcerative colitis drug PALI-2108 gets boost from new IBD advisor - Stock Titan
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com UK
Can Palisade Bio Inc. (7NS0) stock resist broad market declinesPortfolio Risk Report & Precise Trade Entry Recommendations - mfd.ru
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock By Investing.com - Investing.com Australia
Palisade Bio CEO Finley sells $6818 in shares - Investing.com South Africa
Palisade Bio CEO Finley sells $6818 in shares By Investing.com - Investing.com India
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Palisade Bio Inc. maintain sales growthJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Palisade Bio (PALI) awards Chief Medical Officer 787,000 RSUs - Stock Titan
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewswire
Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Aug Shorts: Will Palisade Bio Inc outperform its industry peers2025 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug Sentiment: Is Palisade Bio Inc stock a good pick for beginners2025 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Palisade Bio leaders set for virtual Oppenheimer healthcare conference slot - Stock Titan
Franklin Resources Inc's Strategic Acquisition of Palisade Bio I - GuruFocus
Palisade Bio Inc (PALI) 財務データ
収益
当期純利益
現金流量
EPS
Palisade Bio Inc (PALI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
1.76%
0.09%
大文字化:
|
ボリューム (24 時間):